INTERNATIONAL MULTICENTRE COMPARISON OF CERIVASTATIN WITH PLACEBO AND SIMVASTATIN FOR THE TREATMENT OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLAEMIA
Author:
- 1 June 1999
- journal article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 53 (4) , 243-250
Abstract
No abstract availableFunding Information
- Bayer
This publication has 14 references indexed in Scilit:
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Efficacy and Safety of 0.8 mg Dosage of Cerivastatin, a Novel HMG-CoA Reductase InhibitorJACC, 1998
- 127 Pharmacokinetics of single dose cerivastatin in subjects with normal and impaired renal functionAtherosclerosis, 1997
- 109 Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxinAtherosclerosis, 1997
- 103 Phase I study to investigate the effects of cimetidine on the pharmacokinetics of cerivastatin—a new HMG-CoA reductase inhibitorAtherosclerosis, 1997
- Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary HypercholesterolemiaJournal of Cardiovascular Pharmacology and Therapeutics, 1997
- No Pharmacokinetic or Pharmacodynamic Interaction Between Rivastatin and WarfarinThe Journal of Clinical Pharmacology, 1995
- Inhalation of levomepromazine in severe acute asthmaThe Lancet, 1994
- Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductaseThe American Journal of Cardiology, 1994
- Physiological Disposition of Hmg-Coa-Reductase InhibitorsDrug Metabolism Reviews, 1990